Genetic-Guided Pharmacotherapy for Coronary Artery Disease: A Systematic and Critical Review of Economic Evaluations.
Lim KK. et al, (2024), J Am Heart Assoc
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Kovács G. et al, (2023), Per Med
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Nagy B. et al, (2023), Per Med
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Koleva-Kolarova R. et al, (2023), Per Med
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
Szilberhorn L. et al, (2023), Personalized Medicine
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
Koleva-Kolarova R. et al, (2023), Personalized Medicine
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
Koleva-Kolarova R. et al, (2023), Personalized Medicine
Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.
Vellekoop H. et al, (2023), Per Med, 20, 321 - 338
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib.
Huygens S. et al, (2022), Value Health
A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations.
Lim KK. et al, (2022), Pharmacoeconomics
IT Evaluation of Foundation Healthcare Group NHS Vanguard programme: IT simultaneously an enabler and a rate limiting factor.
Tapuria A. et al, (2022), Informatics for health & social care, 47, 317 - 325
REIMBURSEMENT PATHWAY FOR ADVANCED THERAPY MEDICINAL PRODUCTS IN BULGARIA
Djambazov S. et al, (2022), VALUE IN HEALTH, 25, S472 - S472
TARGETED AND IMMUNOTHERAPIES FOR CANCER - REIMBURSEMENT AND EXPENDITURE IN A SINGLE-PAYER HEALTHCARE SYSTEM IN BULGARIA
Encheva-Malinova M. et al, (2022), VALUE IN HEALTH, 25, S477 - S477
Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients.
Tsiachristas A. et al, (2022), BMC Cancer, 22
The net benefit of personalised medicine: A systematic literature review and regression analysis.
Vellekoop H. et al, (2022), Value in Health
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options Article
Koleva-Kolarova R. et al, (2022), Applied Health Economics and Health Policy
WHAT IS THE NET ADDED VALUE OF PERSONALISED MEDICINE? A SYSTEMATIC LITERATURE REVIEW
Vellekoop H. et al, (2022), VALUE IN HEALTH, 25, S75 - S75
IT Evaluation of Foundation Healthcare Group NHS Vanguard programme: IT simultaneously an enabler and a rate limiting factor.
Tapuria A. et al, (2021), Inform Health Soc Care, 1 - 9
Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations
Lim KK. et al, (2021), The Pharmacogenomics Journal